SHINE, Phoenix merger focused on advancing fusion technology
SHINE Medical Technologies LLC and Phoenix LLC today announced that the companies have completed a merger under which Phoenix has become a wholly owned subsidiary of SHINE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420006038/en/
Greg Piefer, CEO of SHINE (left), talks with Evan Sengbusch, general manager of SHINE's Phoenix division, and Ross Radel, chief technology officer and chief operating officer of the Phoenix division, at the Phoenix headquarters and manufacturing center in Fitchburg, Wis., on April 16, 2021. (Photo: SHINE Medical Technologies)
SHINE is a next-generation nuclear technology company focused on unlocking the power of fusion technologies to benefit the planet and humankind. The company’s goal is to deliver on the long-term promise of clean fusion energy by advancing fusion technology starting with the commercialization of medical isotopes. Phoenix designs and manufactures the world’s strongest steady-state fusion neutron generators used for advanced industrial imaging and other applications for improving safety and quality in the aerospace, defense, medical and energy sectors.
The combined company represents the first two phases of the long-term vision of Greg Piefer, the founder of both companies, for producing clean energy from fusion (see “SHINE’s Four-Phase Progression to Clean Energy Production” below). The goal of each phase of SHINE’s approach is to build additional capacity and capability, and deepen scientific understanding of fusion technology as it progresses to clean fusion energy production. Each step through the four phases is expected to provide further proof of the technology’s robustness, a foundation for ongoing innovation in the next phase and the creation of value for the company, its customers, and shareholders.
“SHINE and Phoenix have shared a common long-term vision and operated in close collaboration during the past 11 years, but it’s always been inefficient to operate as separate companies,” said Greg Piefer, CEO of SHINE. “Coming together will enable us to advance fusion technology more quickly by aligning interests and combining complementary core competencies. Through the four phases, we are taking a deliberate approach to building a company that can ultimately deliver cost-effective, clean fusion energy to billions, while serving important near-term market needs like advanced industrial imaging and medical isotopes, along the way.” For a video of additional comments from Greg Piefer, please click here (:46 broadcast-quality available for the media).
Phoenix has developed a strong track record of commercialization and revenue generation by applying its fusion-based technology to applications such as advanced industrial imaging, which can image modern materials in great detail, addressing quality assurance and safety needs in the aerospace, defense, energy, and other industries. These applications are part of Phase 1 of the four-phase approach.
The second phase of the approach involves applications of nuclear fusion to replace nuclear reactors used in the production of life-saving medical isotopes for diagnostic imaging, like molybdenum-99 (Mo-99), and with potential use as cancer therapeutics like lutetium-177 (Lu-177). This month, SHINE kicked off Phase 2 commercialization when it began producing Lu-177. In 2022, SHINE expects to commence production of up to 20 million doses of Mo-99 per year in its fusion-powered production facility in Janesville, Wis. The facility is expected to be the world’s largest-capacity medical isotope production plant.
“This merger is a natural evolution of our strong existing partnership with SHINE, rooted in our common origin and shared mission,” said Evan Sengbusch, general manager of SHINE’s Phoenix division. “Phoenix’s track record of successfully deploying our core neutron generation technology across multiple demanding market sectors has provided important commercial validation and risk reduction for critical technologies that underpin execution in Phase 2. We are excited to join with SHINE and leverage our complementary nuclear capabilities to advance towards clean fusion energy production.” For a video of additional comments from Evan Sengbusch, please click here (1:24 broadcast-quality available for the media).
Phoenix was founded in 2005 by Piefer to develop and commercialize a unique technology that generated neutrons through fusion. He spun SHINE out of Phoenix in 2010 to apply that technology to medical isotope production and other applications through the four-phase approach.
Evercore Group L.L.C. served as exclusive financial advisor to SHINE. Foley & Lardner served as lead legal counsel to SHINE. SVB Leerink served as exclusive financial advisor to Phoenix. Godfrey & Kahn S.C. served as lead legal counsel to Phoenix.
SHINE’s Four-Phase Progression to Clean Energy Production
- Phase 1: Advanced industrial imaging – uses neutrons for detailed imaging to improve the quality and safety of products in the aerospace, defense, energy, and other industries.
- Phase 2: Medical isotopes (small-scale transmutation) – uses fusion technology to produce medical isotopes that diagnose and treat heart disease, cancer and a wide range of diseases
- Phase 3: Nuclear waste recycling (large-scale transmutation) – scale up of phase 2 processing and fusion technology to recycle nuclear waste
- Phase 4: Fusion Energy – establishes nuclear fusion as a technically and commercially viable global source of energy
About SHINE Medical Technologies
SHINE is a nuclear technology company committed to improving the lives of people and the planet. The company is focusing its fusion-based technology initially on advanced industrial imaging and the production of diagnostic and therapeutic isotopes. These isotopes include molybdenum-99, a diagnostic isotope used to diagnose heart disease, cancer, and other conditions, and lutetium-177, a therapeutic isotope that holds the promise of significantly improving the outcome of some cancer patients. SHINE has a long-term strategy to solve some of humanity’s biggest problems, including nuclear waste recycling and the production of clean fusion energy, in addition to advanced industrial imaging and medical isotopes, by pursuing our vision for progressively broad and impactful uses of fusion technology. For more information about SHINE, please visit our website at www.shinemed.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420006038/en/
Contact information
MALLORY PROUTY
CORPORATE COMMUNICATIONS PROJECT MANAGER, MBA
P: 608-530-5606 | M: 630-945-2379
mallory.prouty@shinemed.com
ROD HISE
DIRECTOR OF STRATEGIC COMMUNICATIONS
P 608-530-5659 | M 608-770-7850
rod.hise@shinemed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Participate in Stifel 2025 Healthcare Conference5.11.2025 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP36
Xiid Launches Elite Advisory Board, Enlists Rachel Higham to Help Drive Next Phase of Growth5.11.2025 13:00:00 EET | Press release
Xiid Corp., which is revolutionizing cyber defense with zero knowledge networking, today announced it has assembled a distinguished advisory board and added Rachel Higham to this circle of trusted advisors. Formerly Marks & Spencer’s chief digital and technology officer, Higham will serve as a special advisor and consultant, leading Xiid’s go-to-market strategy with hyperscalers, colocation companies and telecom services providers. “Rachel contributes valuable perspective and experience,” said Xiid CEO Steve Visconti. “Now the new Xiid Advisory Board – which already includes global industry leaders with deep roots at such companies as Alcatel, Capgemini, Deloitte, Microsoft and Vodafone – is even stronger.” Higham learned of Xiid’s unique approach during her time with Marks & Spencer. In addition to her experience with the multinational retailer, she served as WPP’s CIO, BT’s managing director of IT and MD Asia and Vodafone’s head of cloud and infrastructure centre of excellence. “Xiid
Watchmaker Genomics Launches TAPS+, Expanding Multimodal Capabilities in Oncology Ahead of AMP 20255.11.2025 13:00:00 EET | Press release
Watchmaker Genomics today announced the launch of TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology, with the power to advance applications in translational oncology, early cancer detection, therapy response monitoring, fragmentomics, and minimal residual disease assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105264633/en/ Watchmaker Genomics launches TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. Key features of the TAPS+ chemistry Traditional methylation analysis techniques, such as bisulfite treatment, effectively collapse sequence diversity from four bases to three while often damaging DNA. TAPS+ overcomes these limitations with a positive-readout chemistry that
Outreach Bolsters its EMEA Presence and Enhances Customer Experience with New General Manager5.11.2025 12:00:00 EET | Press release
Outreach, the AI Revenue Workflow Platform, is amplifying its EMEA presence by hiring Paul Ditchfield as its new General Manager of EMEA. This move strengthens Outreach’s already vast presence in EMEA with offices in London and Prague, and a data center in Ireland. Ditchfield will lead Outreach’s rapidly growing EMEA team, working closely with customers such as SAP, Siemens, and Omniplex, and expanding Outreach’s presence across EMEA. With twenty-five years of experience in enterprise sales, Ditchfield brings a proven track record of leading revenue teams at Box, ON24, Adobe, and Global Graphics Software. “The rapid rise of AI advancements in EMEA makes it an even more exciting time for the revenue orchestration space,” said Abhijit Mitra, Outreach CEO. “Paul’s leadership and deep understanding of the enterprise software market will be instrumental in guiding our customers through this new era of AI-powered sales, scaling our operations, and delivering Outreach’s full platform capabili
Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 20265.11.2025 11:30:00 EET | Press release
As the 100-day countdown to the Olympic Winter Games continues, and in a year the global Corona brand is celebrating its 100th anniversary, Corona Cero is officially set to bring golden moments to the slopes of Milano Cortina 2026. As the first no-alcohol beer sponsor of the Winter Olympics, the brand is revving up its “For Every Golden Moment” global platform to invite consumers to celebrate every golden moment any time, any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105994873/en/ Corona Cero's "For Every Golden Moment" Olympic Winter Games What began at the Olympic Games Paris 2024, Corona Cero’s Olympics partnership reinforces that beer and sports are better together by offering consumers more choices for any occasion. Corona Cero’s role reflects AB InBev and the International Olympic Committee’s (IOC) shared commitment to responsible consumption, connecting fans and athletes of a legal drinking age to a fr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom